NEW YORK – VieCure said Monday that it has raised $45 million, which it will put toward advancing its next-generation clinical decision support solution and expanding the scale of its commercial operations.
The financing round, which was led by Northpond Ventures, will support the Denver-based firm's expansion of its artificial intelligence-enabled tool, dubbed the Halo Intelligence platform. The technology is designed to combine clinical decision support and electronic medical records to enable community oncologists to better select treatment paths for individual patients.
VieCure's platform integrates telehealth tools and an oncology information management system, among others. The artificial intelligence platform further incorporates patient data, physician notes, clinical records, treatment responses, radiology images, pathology-based tumor profiles, molecular features, and wearable devices.
So far, VieCure says oncologists use its platform to manage 18,000 patients per day.
In tandem with the funding announcement, VieCure also said on Monday that Richard Daly will join its board of directors as chairman.
"This financing round allows us to accelerate our platform deployments and enhance our industry-leading and patented Halo Intelligence platform," VieCure CEO Michael Power said in a statement.
VieCure has partnered with companies, health systems, and contract research organizations, including Sema4, Laboratory Corporation of America, Exact Sciences, American Oncology Network, TD2, and Clarified Precision Medicine. Most of these collaborations have the stated goal of increasing access to genomic testing and biomarker-based precision oncology trials, especially in the community cancer care setting.